The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

The US Surgeon General released a report directly linking alcohol to cancer. A BI analysis of alcohol spending shows how ...

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

The poll comes as U.S. obesity rates continue to pose a major health problem, leading to high rates of heart disease and diabetes.

Adult obesity rates in the United States dropped from 46% in 2022 to 45.6% in 2023, according to the new study published in ...

(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

In the United States, police rarely face criminal charges when civilians ... Accidental rulings typically blamed preexisting ...

but not for long Eli Lilly is still slightly behind Novo Nordisk in terms of market share of the incretin class in obesity in the United States, but this is more a reflection of the inability of ...

Lilly's own obesity injection - sold as Zepbound in the United States - led to an average weight loss of nearly 23% in clinical trials. The data from Novo's CagriSema Phase III trial was based on ...